Medical devices, healthcare technology and the business of care
PMA approval · P980023

PHYLAX IMPLANTABLE CARDIOVERTER DEFIBRILLATOR SYSTEM

Biotronik, Inc. · Decision date Oct 27, 1998

FDA DECISIONP980023

What did the FDA approve?

FDA records P980023 as an original PMA application. The recorded decision is approval, dated Oct 27, 1998.

FDA approval order statement

Approval for the Phylax Implantable Cardioverter Defibrillator (ICD) System: a) ICD PUlse Generator - Phylax XM ICD, model number 121491; Phylax XM Active Housing ICD, model number 121492; Phylax XM Replacement ICD, model number 121162 and mycroPhylax ICD, model number 121493; b) ICD Lead - SPS 75 Lead System, model number 120398; SL-ICD Lead Systems (SL-ICD 75/13, model number 120395, SL-ICD 75/16, model number 120396, SL-ICD 75/18, model number 120397, SL-ICD 100/13, model number 116414, SL-ICD 100/16, model number 118375, SL-ICD118375, SL-ICD 100/18, model number 119077); Kainox SL Lead Systems (Kainox SL 75/13, model number 124219, Kainox SL 75/16, model number 124218, Kainox SL 75/18, model number 124217, Kainox SL 100/13, model number 124238, Kainox SL 100/16, model number 124239, Kainox SL 100/18, model number 124240); Kainox RV 75 Lead System, model number 124005; and (c) Programming and Monitoring System - TMS 1000 Tachyarrhythmia Monitoring System, and Software Module SWM 1000 F00I01. This device is indicated for use in patients who are at risk of sudden death due to ventricular arrhythmias and have experienced one of the following situations: survival of at least one episode of cardiac arrest (manifested by a loss of consciousness) due to a ventricular tachyarrhythmia; or recurrent poorly tolerated sustained ventricular tachycardia (VT). Note: the clinical outcome for hemodynamically stable VT patients is not fully know. Safety and effectiveness studies for this indication have not been conducted.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Oct 27, 1998

FDA source record

Regulatory record facts

Identifier
P980023
Regulatory pathway
Premarket approval application
Product code
LWS
Decision code
APPR
Decision date
Oct 27, 1998
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implantable cardioverter defibrillator (non-CRT).

Product code
LWS
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P980023 received

    Application receipt date recorded by FDA.

  2. P980023 · FDA decision

    APPR

  3. P980023/S150 · Related supplement

    Pamira S 60; Pamira S 65; Pamira S 75; Pamira SD 60/16; Pamira SD 65/16; Pamira SD 65/18; Pamira SD 75/18; Pamira S DX 6

  4. P980023/S146 · Related supplement

    Acticor Sky VR-T, Rivacor Sky VR-T, Rivacor Rise VR-T, Rivacor Aura VR-T, Acticor Sky VR-T DX, Rivacor Sky VR-T DX, Riva

  5. P980023/S140 · Related supplement

    Ilivia Neo 7 VR-T DX 429530; Intica Neo 7 VR-T DX 429559; Intica Neo 5 VR-T DX 429569

  6. P980023/S151 · Related supplement

    Acticor Sky VR-T, Rivacor Sky VR-T, Rivacor Rise VR-T, Rivacor Aura VR-T, Acticor Sky VR-T DX, Rivacor Sky VR-T DX, Riva

  7. P980023/S149 · Related supplement

    Acticor Sky VR-T 481989; Rivacor Sky VR-T 481984; Rivacor Rise VR-T 482020; Rivacor Aura VR-T 482015; Acticor Sky VR-T D

  8. P980023/S152 · Related supplement

    Ilivia Neo 7 VR-T DX DF-1 ProMRI, Ilivia Neo 7 VR-T DF-1 ProMRI, Intica Neo 7 VR-T DX DF-1 ProMRI, Intica Neo 7 VR-T DF-

  9. P980023/S153 · Related supplement

    Ilivia Neo 7 VRT DX, Intica Neo 7 VRT DX, Intica Neo 5 VRT DX, Acticor Sky VR-T, Rivacor Sky VR-T, Rivacor Rise VR-T, Ri

Timeline entries are records held by MedtechLedger for P980023. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P980023

Explore the linked device profile

Other records with product code LWS

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biotronik, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6024 Jean Rd., Lake Oswego, OR, 97035

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records